[{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Infinimmune Raises $12 Million in Seed Funding to Pioneer Novel Approach to Antibody Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Infinimmune","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Infinimmune Announces Partnership with Grid Therapeutics to Conduct Deep Sequencing of B Cells for Oncology Drug Discovery","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by Infinimmune
Under the partnership, Grid will identify new antibody drug candidates for non-small cell lung cancer, by leveraging Infinimmune’s Anthrobody™ drug discovery platform.
Infinimmune is reinventing antibody drug discovery by focusing solely on human-derived antibody drugs. Inside every human, the equivalent of 100 billion antibody clinical trials are conducted every day, testing each antibody for safety and efficacy in parallel.